Loading…
The effect of food on oral melphalan absorption
Fifteen patients receiving oral melphalan (4.2-5.3 mg/m2) for a variety of neoplastic disorders were studied. Ten patients received the drug on separate occasions, with and without a standardized breakfast. Eight of these patients also received an IV bolus dose (5 mg/m2) to determine bioavailability...
Saved in:
Published in: | Cancer chemotherapy and pharmacology 1986-03, Vol.16 (2), p.194-197 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c377t-dab94b0f4981e1e7986e28e14ad25fff7d728d64ef6de0e9b68b586430863de3 |
---|---|
cites | |
container_end_page | 197 |
container_issue | 2 |
container_start_page | 194 |
container_title | Cancer chemotherapy and pharmacology |
container_volume | 16 |
creator | REECE, P. A KOTASEK, D MORRIS, R. G DALE, B. M SAGE, R. E |
description | Fifteen patients receiving oral melphalan (4.2-5.3 mg/m2) for a variety of neoplastic disorders were studied. Ten patients received the drug on separate occasions, with and without a standardized breakfast. Eight of these patients also received an IV bolus dose (5 mg/m2) to determine bioavailability. Serial melphalan plasma samples were taken over 5 h after administration and assayed by high-performance liquid chromatography. The median area under the curve (AUC) when taken fasting was 179 (range 95-336) ng X h X ml-1, and when taken with food, 122 (47-227) ng X h X ml-1, the median reduction being 39% (P less than 0.01). In one patient, who died before completing the study, the drug was not detectable at all after being taken with food. In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1). In these patients bioavailability was 85% (26-96)% when the drug was taken fasting and 58% (7-99)% when taken with food (P less than 0.025). Median clearance following IV administration was 362 ml/min/m2 (range 104-694). It was found that the melphalan level in a single plasma sample drawn 1.5 h after administration was highly predictive of oral melphalan AUC (rs = 0.915, P less than 0.1). This study suggests that to ensure optimum absorption of the drug, melphalan should not be taken with food. |
doi_str_mv | 10.1007/bf00256176 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76706869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76706869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-dab94b0f4981e1e7986e28e14ad25fff7d728d64ef6de0e9b68b586430863de3</originalsourceid><addsrcrecordid>eNo9kMFLwzAYxYMoc04v3oUcxINQ96VJk_Sow6kw8NJ7SZsvrNI2NekO_vdWVnd6h_fj8fgRcsvgiQGodeUA0kwyJc_IkgmeJqAFPydL4EIkmQJxSa5i_AIAwThfkAXPheaQLcm62CNF57AeqXfUeW-p76kPpqUdtsPetKanpoo-DGPj-2ty4Uwb8WbOFSm2r8XmPdl9vn1snndJzZUaE2uqXFTgRK4ZMlS5lphqZMLYNHPOKatSbaVAJy0C5pXUVaal4KAlt8hX5OE4OwT_fcA4ll0Ta2ynM-gPsVRSgdQyn8DHI1gHH2NAVw6h6Uz4KRmUf3LKl-2_nAm-m1cPVYf2hM42pv5-7k2sTeuC6esmnrDpn2Ap578s_GoM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76706869</pqid></control><display><type>article</type><title>The effect of food on oral melphalan absorption</title><source>Springer Nature - Connect here FIRST to enable access</source><creator>REECE, P. A ; KOTASEK, D ; MORRIS, R. G ; DALE, B. M ; SAGE, R. E</creator><creatorcontrib>REECE, P. A ; KOTASEK, D ; MORRIS, R. G ; DALE, B. M ; SAGE, R. E</creatorcontrib><description>Fifteen patients receiving oral melphalan (4.2-5.3 mg/m2) for a variety of neoplastic disorders were studied. Ten patients received the drug on separate occasions, with and without a standardized breakfast. Eight of these patients also received an IV bolus dose (5 mg/m2) to determine bioavailability. Serial melphalan plasma samples were taken over 5 h after administration and assayed by high-performance liquid chromatography. The median area under the curve (AUC) when taken fasting was 179 (range 95-336) ng X h X ml-1, and when taken with food, 122 (47-227) ng X h X ml-1, the median reduction being 39% (P less than 0.01). In one patient, who died before completing the study, the drug was not detectable at all after being taken with food. In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1). In these patients bioavailability was 85% (26-96)% when the drug was taken fasting and 58% (7-99)% when taken with food (P less than 0.025). Median clearance following IV administration was 362 ml/min/m2 (range 104-694). It was found that the melphalan level in a single plasma sample drawn 1.5 h after administration was highly predictive of oral melphalan AUC (rs = 0.915, P less than 0.1). This study suggests that to ensure optimum absorption of the drug, melphalan should not be taken with food.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/bf00256176</identifier><identifier>PMID: 3948305</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Absorption ; Administration, Oral ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Biological Availability ; Chemotherapy ; Chromatography, High Pressure Liquid ; Fasting ; Female ; Food ; Humans ; Injections, Intravenous ; Kinetics ; Male ; Medical sciences ; Melphalan - administration & dosage ; Melphalan - blood ; Melphalan - metabolism ; Melphalan - therapeutic use ; Middle Aged ; Neoplasms - drug therapy ; Pharmacology. Drug treatments</subject><ispartof>Cancer chemotherapy and pharmacology, 1986-03, Vol.16 (2), p.194-197</ispartof><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-dab94b0f4981e1e7986e28e14ad25fff7d728d64ef6de0e9b68b586430863de3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27906,27907</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8644123$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3948305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>REECE, P. A</creatorcontrib><creatorcontrib>KOTASEK, D</creatorcontrib><creatorcontrib>MORRIS, R. G</creatorcontrib><creatorcontrib>DALE, B. M</creatorcontrib><creatorcontrib>SAGE, R. E</creatorcontrib><title>The effect of food on oral melphalan absorption</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Fifteen patients receiving oral melphalan (4.2-5.3 mg/m2) for a variety of neoplastic disorders were studied. Ten patients received the drug on separate occasions, with and without a standardized breakfast. Eight of these patients also received an IV bolus dose (5 mg/m2) to determine bioavailability. Serial melphalan plasma samples were taken over 5 h after administration and assayed by high-performance liquid chromatography. The median area under the curve (AUC) when taken fasting was 179 (range 95-336) ng X h X ml-1, and when taken with food, 122 (47-227) ng X h X ml-1, the median reduction being 39% (P less than 0.01). In one patient, who died before completing the study, the drug was not detectable at all after being taken with food. In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1). In these patients bioavailability was 85% (26-96)% when the drug was taken fasting and 58% (7-99)% when taken with food (P less than 0.025). Median clearance following IV administration was 362 ml/min/m2 (range 104-694). It was found that the melphalan level in a single plasma sample drawn 1.5 h after administration was highly predictive of oral melphalan AUC (rs = 0.915, P less than 0.1). This study suggests that to ensure optimum absorption of the drug, melphalan should not be taken with food.</description><subject>Absorption</subject><subject>Administration, Oral</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Chemotherapy</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Fasting</subject><subject>Female</subject><subject>Food</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Kinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melphalan - administration & dosage</subject><subject>Melphalan - blood</subject><subject>Melphalan - metabolism</subject><subject>Melphalan - therapeutic use</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNo9kMFLwzAYxYMoc04v3oUcxINQ96VJk_Sow6kw8NJ7SZsvrNI2NekO_vdWVnd6h_fj8fgRcsvgiQGodeUA0kwyJc_IkgmeJqAFPydL4EIkmQJxSa5i_AIAwThfkAXPheaQLcm62CNF57AeqXfUeW-p76kPpqUdtsPetKanpoo-DGPj-2ty4Uwb8WbOFSm2r8XmPdl9vn1snndJzZUaE2uqXFTgRK4ZMlS5lphqZMLYNHPOKatSbaVAJy0C5pXUVaal4KAlt8hX5OE4OwT_fcA4ll0Ta2ynM-gPsVRSgdQyn8DHI1gHH2NAVw6h6Uz4KRmUf3LKl-2_nAm-m1cPVYf2hM42pv5-7k2sTeuC6esmnrDpn2Ap578s_GoM</recordid><startdate>198603</startdate><enddate>198603</enddate><creator>REECE, P. A</creator><creator>KOTASEK, D</creator><creator>MORRIS, R. G</creator><creator>DALE, B. M</creator><creator>SAGE, R. E</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198603</creationdate><title>The effect of food on oral melphalan absorption</title><author>REECE, P. A ; KOTASEK, D ; MORRIS, R. G ; DALE, B. M ; SAGE, R. E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-dab94b0f4981e1e7986e28e14ad25fff7d728d64ef6de0e9b68b586430863de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Absorption</topic><topic>Administration, Oral</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Chemotherapy</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Fasting</topic><topic>Female</topic><topic>Food</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Kinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melphalan - administration & dosage</topic><topic>Melphalan - blood</topic><topic>Melphalan - metabolism</topic><topic>Melphalan - therapeutic use</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>REECE, P. A</creatorcontrib><creatorcontrib>KOTASEK, D</creatorcontrib><creatorcontrib>MORRIS, R. G</creatorcontrib><creatorcontrib>DALE, B. M</creatorcontrib><creatorcontrib>SAGE, R. E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>REECE, P. A</au><au>KOTASEK, D</au><au>MORRIS, R. G</au><au>DALE, B. M</au><au>SAGE, R. E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of food on oral melphalan absorption</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1986-03</date><risdate>1986</risdate><volume>16</volume><issue>2</issue><spage>194</spage><epage>197</epage><pages>194-197</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Fifteen patients receiving oral melphalan (4.2-5.3 mg/m2) for a variety of neoplastic disorders were studied. Ten patients received the drug on separate occasions, with and without a standardized breakfast. Eight of these patients also received an IV bolus dose (5 mg/m2) to determine bioavailability. Serial melphalan plasma samples were taken over 5 h after administration and assayed by high-performance liquid chromatography. The median area under the curve (AUC) when taken fasting was 179 (range 95-336) ng X h X ml-1, and when taken with food, 122 (47-227) ng X h X ml-1, the median reduction being 39% (P less than 0.01). In one patient, who died before completing the study, the drug was not detectable at all after being taken with food. In the eight patients who were also given IV melphalan, the median terminal melphalan half-life (57 min, range 38-71) was no different from its oral half-life [55 (27-104) min fasting; 55 (30-72) min with food] (P greater than 0.1). In these patients bioavailability was 85% (26-96)% when the drug was taken fasting and 58% (7-99)% when taken with food (P less than 0.025). Median clearance following IV administration was 362 ml/min/m2 (range 104-694). It was found that the melphalan level in a single plasma sample drawn 1.5 h after administration was highly predictive of oral melphalan AUC (rs = 0.915, P less than 0.1). This study suggests that to ensure optimum absorption of the drug, melphalan should not be taken with food.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>3948305</pmid><doi>10.1007/bf00256176</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-5704 |
ispartof | Cancer chemotherapy and pharmacology, 1986-03, Vol.16 (2), p.194-197 |
issn | 0344-5704 1432-0843 |
language | eng |
recordid | cdi_proquest_miscellaneous_76706869 |
source | Springer Nature - Connect here FIRST to enable access |
subjects | Absorption Administration, Oral Aged Antineoplastic agents Biological and medical sciences Biological Availability Chemotherapy Chromatography, High Pressure Liquid Fasting Female Food Humans Injections, Intravenous Kinetics Male Medical sciences Melphalan - administration & dosage Melphalan - blood Melphalan - metabolism Melphalan - therapeutic use Middle Aged Neoplasms - drug therapy Pharmacology. Drug treatments |
title | The effect of food on oral melphalan absorption |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A45%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20food%20on%20oral%20melphalan%20absorption&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=REECE,%20P.%20A&rft.date=1986-03&rft.volume=16&rft.issue=2&rft.spage=194&rft.epage=197&rft.pages=194-197&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/bf00256176&rft_dat=%3Cproquest_cross%3E76706869%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c377t-dab94b0f4981e1e7986e28e14ad25fff7d728d64ef6de0e9b68b586430863de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76706869&rft_id=info:pmid/3948305&rfr_iscdi=true |